Arbutus Biopharma Corporation (ABUS) Financial Statements (2024 and earlier)

Company Profile

Business Address 701 VETERANS CIRCLE
WARMINSTER, PA 18974
State of Incorp. BC
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:184,300191,000123,30090,834124,617126,352
Cash and cash equivalents30,776109,28252,25131,79936,94254,292
Short-term investments116,13746,03571,01759,03587,67572,060
Other undisclosed cash, cash equivalents, and short-term investments 37,38735,68332   
Receivables1,3528991,3121,2041,820870
Other undisclosed current assets(34,513)(31,238)3,0921,7902,7922,144
Total current assets:151,139160,661127,70493,828129,229129,366
Noncurrent Assets
Operating lease, right-of-use asset1,7442,0922,405 
Property, plant and equipment5,0705,9836,9278,67610,14512,183
Long-term investments and receivables37,36335,688  22,224 
Long-term investments37,36335,688  22,224 
Intangible assets, net (including goodwill)     66,30783,011
Goodwill     22,47124,364
Intangible assets, net (excluding goodwill)     43,83658,647
Restricted cash and investments      12,601
Other noncurrent assets1036144293  
Other undisclosed noncurrent assets    2,738  
Total noncurrent assets:44,28043,8249,37611,70798,676107,795
TOTAL ASSETS:195,419204,485137,080105,535227,905237,161
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:16,02910,8388,9017,0989,42910,646
Accounts payable3,5203,1742,9942,3983,1921,987
Accrued liabilities5189886889531,180829
Other undisclosed accounts payable and accrued liabilities11,9916,6765,2193,7475,0577,830
Deferred revenue16,456   
Restructuring reserve    1371,331 
Deferred revenue and credits2,742
Other undisclosed current liabilities3723836405934791,239
Total current liabilities:32,85711,2219,5417,82811,23914,627
Noncurrent Liabilities
Long-term debt and lease obligation  2,2312,593  12,001
Long-term debt, excluding current maturities      12,001
Liabilities, other than long-term debt15,3455,2983,4262,9533,77128,060
Deferred revenue and credits693
Deferred revenue 5,999   
Deferred rent credit     645
Deferred tax liabilities, net 16,943
Operating lease, liability1,8152,2312,593 
Business combination, contingent consideration, liability7,5315,2983,4262,9533,12610,424
Other undisclosed noncurrent liabilities10,36516,29619,55422,01012,661 
Total noncurrent liabilities:25,71023,82525,57324,96316,43240,061
Total liabilities:58,56735,04635,11432,79127,67154,688
Equity
Equity, attributable to parent, including:136,852169,439101,96672,744200,234182,473
Preferred stock      48,869
Common stock1,318,7371,286,636985,939898,535879,405876,108
Additional paid in capital72,40665,48560,75155,24648,08442,840
Accumulated other comprehensive loss(50,488)(48,335)(48,171)(48,229)(48,170)(48,185)
Accumulated deficit(1,203,803)(1,134,347)(1,045,961)(970,093)(805,221)(738,070)
Other undisclosed equity, attributable to parent   149,408137,285126,136911
Total equity:136,852169,439101,96672,744200,234182,473
TOTAL LIABILITIES AND EQUITY:195,419204,485137,080105,535227,905237,161

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues39,01910,9886,9146,0115,94510,700
Revenue, net10,700
Premiums earned, net     
Gross profit:39,01910,9886,9146,0115,94510,700
Operating expenses(104,475)(84,510)(64,720)(150,085)(95,725)(121,630)
Operating loss:(65,456)(73,522)(57,806)(144,074)(89,780)(110,930)
Nonoperating income (expense)444(2,725)(5,939)(22,305)28,4382,197
Investment income, nonoperating2,1921277412,11127,9311,538
Gain (loss), foreign currency transaction, before tax(22)5(124)41(1,003)2,301
Interest and debt expense(1,726)(2,857)(4,011)(2,108)(226)(261)
Other undisclosed income from continuing operations before equity method investments, income taxes     226261
Loss from continuing operations before equity method investments, income taxes:(66,738)(79,104)(67,756)(168,487)(61,342)(108,733)
Other undisclosed income (loss) from continuing operations before income taxes  4,0112,108  
Loss from continuing operations before income taxes:(66,738)(79,104)(63,745)(166,379)(61,342)(108,733)
Income tax expense (benefit) (4,444)  12,6564,28224,320
Loss from continuing operations:(71,182)(79,104)(63,745)(153,723)(57,060)(84,413)
Loss before gain (loss) on sale of properties:(79,104)(63,745)(153,723)(57,060)(84,413)
Net loss:(71,182)(79,104)(63,745)(153,723)(57,060)(84,413)
Other undisclosed net income attributable to parent1,7262,857    
Net loss attributable to parent:(69,456)(76,247)(63,745)(153,723)(57,060)(84,413)
Preferred stock dividends and other adjustments  (12,139)(12,123)(11,149)(10,091)(911)
Net loss available to common stockholders, diluted:(69,456)(88,386)(75,868)(164,872)(67,151)(85,324)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(71,182)(79,104)(63,745)(153,723)(57,060)(84,413)
Other comprehensive income (loss) (2,153)(164)14(59)15 
Other undisclosed comprehensive loss      
Comprehensive loss:(73,335)(79,268)(63,731)(153,782)(57,045)(84,413)
Comprehensive income, net of tax, attributable to noncontrolling interest   44   
Other undisclosed comprehensive income, net of tax, attributable to parent1,7262,857    
Comprehensive loss, net of tax, attributable to parent:(71,609)(76,411)(63,687)(153,782)(57,045)(84,413)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: